TY - JOUR
T1 - Prognostic significance of dysadherin expression in advanced colorectal carcinoma
AU - Aoki, S.
AU - Shimamura, T.
AU - Shibata, T.
AU - Nakanishi, Y.
AU - Moriya, Y.
AU - Sato, Y.
AU - Kitajima, M.
AU - Sakamoto, M.
AU - Hirohashi, S.
N1 - Funding Information:
We thank Ms Y Yamauchi for her expert technical assistance. S Aoki and T Shimamura contributed equally to this work. S Aoki and T Shimamura are Awardees of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research in Japan. This research was supported in part by a Grant-in-Aid for the Second Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan, and by a Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Science, Sports and Culture.
PY - 2003/3/10
Y1 - 2003/3/10
N2 - A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P = 0.003). The increased expression of dysadherin had a significant impact on patient survival (P = 0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P = 0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.
AB - A novel glycoprotein, dysadherin, has an anti-cell - cell adhesion function through downregulating E-cadherin. In this study, we investigated the expressions of dysadherin and E-cadherin in 82 patients with stage II and III colorectal carcinomas to determine the correlation between the two molecules and the clinicopathologic features of each tumour. Dysadherin was not expressed in normal colorectal epithelium. Fifty-one per cent of tumours showed dysadherin immunopositivity in over 50% of cancer cells. Thirty-eight per cent of tumours showed reduced E-cadherin immunopositivity. The increased expression of dysadherin was significantly associated with lung metastasis (P = 0.003). The increased expression of dysadherin had a significant impact on patient survival (P = 0.0099 and 0.0036, log-rank test for overall and recurrence-free survival rate, respectively). Furthermore, tumour with increased expression of dysadherin and reduced expression of E-cadherin showed the worst prognosis (P = 0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rate, respectively). These results suggest that increased dysadherin expression is a significant indicator of poor prognosis for patients with advanced colorectal carcinoma.
KW - Colorectal carcinoma
KW - Dysadherin
KW - Immunohistochemistry
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=0037430034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037430034&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6600778
DO - 10.1038/sj.bjc.6600778
M3 - Article
C2 - 12618882
AN - SCOPUS:0037430034
VL - 88
SP - 726
EP - 732
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 5
ER -
